RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
16,08 US$
arrow_downward
-1,17%(-0,19) 1D
13 ნოე, 16:00:00 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RARE...
Open
16,30 US$
High
16,32 US$
Low
15,85 US$
Mkt. cap
1,64 მლრდ.
Avg. vol.
3,71 მლნ.
Volume
1,68 მლნ.
52-wk high
39,89 US$
52-wk low
12,73 US$
EPS
-5,19 US$
Beta
0,37
Shares outstanding
101,92 მლნ.
No. of employees
1 ათ.
Open
16,30 US$
High
16,32 US$
Low
15,85 US$
Mkt. cap
1,64 მლრდ.
Avg. vol.
3,71 მლნ.
Volume
1,68 მლნ.
52-wk high
39,89 US$
52-wk low
12,73 US$
EPS
-5,19 US$
Beta
0,37
Shares outstanding
101,92 მლნ.
No. of employees
1 ათ.
News stories
From web sources and news partners
TradingKey
·
5 საათის წინ
S&P 500 Forecast: Index Poised to Retest Record High in November After 500-Point Pullback, Biggest Daily Gain in Nearly Seven Months
Foreign Policy Journal
·
4 საათის წინ
Dow Jones Industrial Average (DJIA) Stays Green While Nasdaq Tumbles Nearly 1% In Sharp Rotation Trade
TradingView
·
12 საათის წინ
EXCLUSIVE: S&P 500’s Sell-Off Tested Buffered ETFs: Expert Explains Why a 10% Buffer May Not Protect You as Expected
Traders Union
·
12 საათის წინ
Michael Kantro: Institutional investors focus on stock picking as S&P 500 targets have lost relevance
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOემილ კაკისი
Employees1,37 ათ.
Founded2010
HeadquartersNovato, კალიფორნია, ამერიკის შეერთებული შტატები
SectorHealth Care
Industry-
Websiteultragenyx.com